Addition of ATG to non-myeloablative peripheral blood haploidentical transplant with PTCY decreases acute GVHD rates and improves GVHD-relapse free survival

Bone Marrow Transplant. 2023 Jun;58(6):723-726. doi: 10.1038/s41409-023-01956-y. Epub 2023 Mar 23.

Authors

Maxime Jullien¹, Amandine Le Bourgeois¹, Pierre Peterlin¹, Alice Garnier¹, Thierry Guillaume^{1

2}, Marie C Béné^{2

3}, Patrice Chevallier^{4

5}

Affiliations

¹ Hematology Department, Nantes University Hospital, Nantes, France.
² INSERM UMR1232, CRCINA IRS-UN, University of Nantes, Nantes, France.
³ Hematology Biology, Nantes University Hospital, Nantes, France.
⁴ Hematology Department, Nantes University Hospital, Nantes, France. patrice.chevallier@chu-nantes.fr.
⁵ INSERM UMR1232, CRCINA IRS-UN, University of Nantes, Nantes, France. patrice.chevallier@chu-nantes.fr.

PMID: 36959369
DOI: 10.1038/s41409-023-01956-y

No abstract available

Publication types

Letter

MeSH terms

Antilymphocyte Serum
Cyclophosphamide
Graft vs Host Disease* / prevention & control
Hematopoietic Stem Cell Transplantation*
Humans
Retrospective Studies
Transplantation Conditioning

Substances

Cyclophosphamide
Antilymphocyte Serum